Table 6.
Multivariable logistic regression analysis on the five outcome variables
| Variable | OR for Decreased GFR (n = 62/1378) (95% CI) | P Value | OR for Hypomagnesemia (n = 36/534) (95% CI) | P Value | OR for Hypophosphatemia (n = 17/572) (95% CI) | P Value | Albuminuria (n = 184/1269) (95% CI) | P Value | OR for Elevated BP (n = 196/1328) (95% CI) | P Value |
|---|---|---|---|---|---|---|---|---|---|---|
| Cumulative ifosfamide dose (per 10 g/m2) | 1.62 (1.44–1.82) | <0.001 | 1.08 (0.87–1.34) | 0.48 | 1.02 (0.82–1.27) | 0.87 | 1.34 (1.23–1.46) | <0.001 | 1.05 (0.94–1.18) | 0.36 |
| Cumulative cisplatin dose (per 100 mg/m2) | 1.29 (1.08–1.54) | 0.005 | 1.66 (1.34–2.05) | <0.001 | 1.00 (0.77–1.30) | 0.99 | 0.95 (0.81–1.12) | 0.54 | 1.13 (0.98–1.28) | 0.09 |
| Cumulative carboplatin dose (per 100 mg/m2) | 1.03 (1.00–1.07) | 0.05 | 0.97 (0.87–1.07) | 0.51 | 1.00 (0.92–1.07) | 0.87 | 1.02 (1.00–1.04) | 0.13 | 0.98 (0.95–1.02) | 0.35 |
| High-dose cyclophosphamide (no/yes) | 7.08 (2.72–18.45) | <0.001 | 2.98 (0.92–9.63) | 0.07 | 0.63 (0.08–5.22) | 0.67 | 0.82 (0.43–1.57) | 0.55 | 1.16 (0.56–2.43) | 0.69 |
| High-dose methotrexate (no/yes) | 0.60 (0.19–1.85) | 0.37 | 1.32 (0.43–4.05) | 0.63 | 0.34 (0.07–1.76) | 0.20 | 1.37 (0.87–2.14) | 0.17 | 0.66 (0.39–1.11) | 0.12 |
| Nephrectomy (no/yes) | 8.56 (3.42–21.42) | <0.001 | 17.46 (4.63–65.79) | <0.001 | 0.70 (0.06–8.26) | 0.78 | 1.70 (0.97–2.96) | 0.06 | 1.55 (0.88–2.71) | 0.13 |
| Total-body irradiation (no/yes) | 1.72 (0.20–15.13) | 0.62 | –a | –a | –a | –a | 2.73 (0.95–7.90) | 0.06 | 1.91 (0.52–6.94) | 0.33 |
| Abdominal irradiation (no/yes) | 1.50 (0.62–3.63) | 0.37 | 0.30 (0.06–1.47) | 0.14 | 1.16 (0.11–12.47) | 0.91 | 1.10 (0.57–2.16) | 0.77 | 2.48 (1.36–4.54) | 0.003 |
| Age at diagnosis (in yr) | 1.05 (0.97–1.13) | 0.22 | 1.05 (0.96–1.16) | 0.27 | 1.10 (0.98–1.24) | 0.11 | 1.02 (0.98–1.06) | 0.41 | 1.07 (1.02–1.11) | 0.002 |
| Time since diagnosis (per 5 yr) | 1.34 (1.04–1.72) | 0.02 | 1.55 (1.09–2.20) | 0.02 | 0.97 (0.61–1.55) | 0.90 | 1.13 (0.98–1.31) | 0.09 | 1.47 (1.28–1.69) | <0.001 |
| Male sex | 1.45 (0.72–2.57) | 0.21 | 0.97 (0.46–2.05) | 0.93 | 0.36 (0.12–1.05) | 0.06 | 0.80 (0.58–1.11) | 0.18 | 2.09 (1.47–2.98) | <0.001 |
| BMI | ||||||||||
| <25 kg/m2 | –b | –b | –b | –b | –b | –b | –b | –b | 1.00 (reference) | |
| ≥25–< 30 kg/m2 | –b | –b | –b | –b | –b | –b | –b | –b | 1.94 (1.27–2.96) | 0.002 |
| ≥30 kg/m2 | –b | –b | –b | –b | –b | –b | –b | –b | 5.93 (3.18–11.07) | <0.001 |
All therapies were modeled as independent risk factors. BMI, body mass index; CI, confidence interval; OR, odds ratio.
a
Not included in regression model because of too few individuals.
b
Not included in regression model.